登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>VEGF164 >VE4-M82Q3

Biotinylated Mouse VEGF164 Protein, His,Avitag™

分子别名(Synonym)

RP1-261G23.1,MGC70609,MVCD1,VEGFA,VPF

表达区间及表达系统(Source)

Biotinylated Mouse VEGF164, His,Avitag (VE4-M82Q3) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 190 (Accession # Q00731-2).

Predicted N-terminus: His

Request for sequence

蛋白结构(Molecular Characterization)

VEGF164 Structure

This protein carries a polyhistidine tag at the N-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 22.5 kDa. The protein migrates as 28-33 kDa under reducing (R) condition, and 46-60 kDa under non-reducing (NR) condition (SDS-PAGE) due to different glycosylation.

标记(Labeling)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Protein Ratio)

Passed as determined by the HABA assay / binding ELISA.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

VEGF164 SDS-PAGE

Biotinylated Mouse VEGF164, His,Avitag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

 

活性(Bioactivity)-ELISA

VEGF164 ELISA

Immobilized VEGFR1/R2 ,C-Fc at 2 μg/mL (100 μL/well) can bind Biotinylated Mouse VEGF164, His,Avitag (Cat. No. VE4-M82Q3) with a linear range of 0.1-3 ng/mL (QC tested).

Protocol

VEGF164 ELISA

Immobilized Human VEGF R1, His Tag at 2 μg/mL (100 μL/well) can bind Biotinylated Mouse VEGF164, His,Avitag (Cat. No. VE4-M82Q3) with a linear range of 0.2-5 ng/mL (Routinely tested).

Protocol

 

活性(Bioactivity)-BLI

VEGF164 BLI

Loaded Biotinylated Mouse VEGF164, His,Avitag (Cat. No. VE4-M82Q3) on SA Biosensor, can bind Mouse VEGF R1, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. VE1-M5256) with an affinity constant of 42.4 pM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

VEGF164 BLI

Loaded Biotinylated Mouse VEGF164, His,Avitag (Cat. No. VE4-M82Q3) on SA Biosensor, can bind Mouse VEGF R2, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. VE2-M5258) with an affinity constant of 1.33 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

 

背景(Background)

Vascular endothelial growth factor A (VEGFA) is also known as Vascular permeability factor (VPF). VEGFA belongs to the PDGF/VEGF growth factor family. VEGFA is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. VEGFA is produced by a group of three major isoforms as a result of alternative splicing and if any three isoforms are produced (VEGFA120, VEGFA164, and VEGFA188) then this will not result in vessel defects and death of the full VEGFA knockout in mice.

 

前沿进展

 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
VEGF164靶点信息
英文全称:Vascular endothelial growth factor A
中文全称:血管内皮生长因子A
种类:Homo sapiens
上市药物数量:40详情
临床药物数量:63详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定